Vektor Medical Highlights vMap Ablation Success in EP Europace Study
Vektor Medical Announces EP Europace Publication: vMap-Guided Ablation Associated with Improved One-Year Arrhythmia-Free Survival in Unstable Ventricular Tachycardia Patients Vektor Medical, a medical technology company transforming cardiac arrhythmia care, today announced the publication of a peer-reviewed study in EP Europace evaluating vMap-guided…
Dialed Moods Pushes Biohacking Forward with Natural Supplement Breakthroughs
Dialed Moods Advances Biohacking Wellness with Nature-Driven Supplement Innovation Dialed Moods, a leading health and wellness company, expands its focus in 2026 on holistic biohacking through plant-powered formulations. Dialed Moods products enable individuals to integrate biohacking into their routines through…
Regional Dermatology Partners with Epiphany Dermatology
Regional Dermatology Joins Epiphany Dermatology Epiphany Dermatology, a leading dermatology company committed to improving access to exceptional dermatologic care, announced today it has expanded its presence in Missouri through its partnership with Regional Dermatology, LLC. Founded in 2010 by Sarah…
Prime Healthcare Foundation Broadens National Presence with Addition of Central Maine Healthcare
Prime Healthcare Foundation Expands National Footprint as Central Maine Healthcare Joins Its Award-Winning System Prime Healthcare Foundation (PHF), a public nonprofit 501(c)(3) charity, announced today that Central Maine Healthcare (CMH) has officially joined its national, award-winning health system, expanding the…
RestorixHealth Reveals Winners of Its 2025 Center Recognition Awards Program
RestorixHealth Announces 2025 Center Recognition Awards Program Recipients RestorixHealth, the nation’s leading wound care solutions company, is pleased to announce the wound and hyperbaric center recipients of their Center Recognition Awards program for the awards period July-December 2025. These prestigious…
VB Spine Moves to Secure Exclusive Rights to Augmedics’ Spine Technology Platform
VB Spine Announces Intent to Acquire Exclusive Rights to Augmedics’ Spine Platform VB Spine LLC the largest privately held spine company, today announced it has entered into a definitive agreement to acquire exclusive rights to the xvision Spine System® (xvision)…
DeciBio Consulting Unveils Data Report on Oncology Genomics Trends Across Europe
Europe Oncology Genomics Tracker Captures Oncologist Perspectives Across Major European Markets – Data Report by DeciBio Consulting LLC A new survey-based Genomics Tracker focused on the EU-5 (France, Germany, Italy, Spain, and the United Kingdom) by DeciBio Consulting LLC provides updated insight…
LocumTenens.com Recognized for Service Excellence with ClearlyRated’s 2026 Staffing Awards
LocumTenens.com Wins ClearlyRated’s 2026 Best of Staffing Client and Talent Awards for Service Excellence LocumTenens.com, a pioneer in healthcare staffing solutions, announced today that it has won ClearlyRated’s Best of Staffing® Awards in both the Client and Talent categories. Marking the organization’s 13th consecutive…
Worldwide Clinical Trials Finalizes Acquisition of Catalyst Clinical Research
Worldwide Clinical Trials Completes Acquisition of Catalyst Clinical Research Worldwide Clinical Trials a global contract research organization (CRO), has completed its acquisition of Catalyst Clinical Research, LCC (“Catalyst”) – a specialized oncology CRO and scalable functional service provider (FSP). This strategic transaction creates a…
ECCO Data Highlight Remsima™ SC’s Ability to Restore and Sustain Disease Control After Treatment Break
New ECCO data show subcutaneous (SC) infliximab (Remsima™ SC) effectively recaptures and maintains disease control after drug holiday Celltrion, Inc. today announced new data from a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), showing that subcutaneous (SC) infliximab…
MEDIPOST Inc. Submits IND Amendment to FDA to Begin Phase III Study
MEDIPOST Inc. Submits IND Amendment With U.S. Food and Drug Administration to Initiate Phase III Trial MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative diseases, announced today that it has filed an…
Enrollment Completed in Alto Neuroscience’s Phase 2 Proof-of-Concept Trial of ALTO-101
Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia Alto Neuroscience, Inc. a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the…